What stage is your pipeline at?
We share pipeline composition and maturity in aggregate — see the Pipeline section above for our current stage distribution by dosage form. Program-level stage detail is reserved for qualified partners under NDA.
What is your IP position?
4 patents filed to date, spanning our complex injectable and advanced-delivery development programs.
Which markets are you targeting for commercialisation?
In order of priority: the United States, the EU (EMA) and UK, Canada, and Latin America.
How large is your team?
50+ people globally, spanning R&D, regulatory, IP, and commercial functions across our UK and India operations.
How capital-efficient is your model?
Financial and capital efficiency detail is reserved for qualified partners and investors under NDA.
What's your competitive edge?
Beyond our dual-hub model and formulation depth: real agility and discipline as a focused organisation, and a willingness to own and fund development risk ourselves. By the time a program reaches a partner, much of the de-risking has already happened at our expense, not theirs.
Do you offer co-development and co-investment on products?
Yes. Our portfolio includes both models: programs we self-fund through to a de-risked, licensable state, and programs structured as collaborations from an earlier stage, where co-investment and risk-sharing are explored jointly with the partner.
Are you open to other markets?
Yes — while our current priority markets are the US, EU/UK, Canada, and Latin America, we're open to discussing other geographies where there's a clear fit with a partner's footprint or a program's commercial opportunity.